{"id":789,"date":"2017-02-14T08:56:49","date_gmt":"2017-02-14T07:56:49","guid":{"rendered":"http:\/\/intervacc.se\/en\/?page_id=789"},"modified":"2024-09-23T18:17:57","modified_gmt":"2024-09-23T16:17:57","slug":"investors","status":"publish","type":"page","link":"https:\/\/intervacc.se\/en\/investors\/","title":{"rendered":"Investors"},"content":{"rendered":"

Intervacc develops veterinary vaccines based on fusions of recombinant proteins. Our first proprietary vaccine Strangvac\u00ae<\/sup>, a vaccine against the streptococcal infection strangles that affects horses, is now available in several important European markets. Strangvac\u00ae<\/sup> addresses a severe (fatal), common and highly contagious global disease. It is a vaccine with great coverage against all globally circulating Streptococcus equi<\/em> strains, with the potential to be a game changer in the fight against this devastating disease.<\/p>\n

In addition to Strangvac\u00ae<\/sup><\/a>, we have an exciting development portfolio of veterinary vaccine projects<\/a> that are in a pre-clinical phase.<\/p>\n

The Intervacc group also include Nordvacc<\/a>, who markets and distribute products within the Animal Health segment in the Nordics. Mybac-Vettech<\/a> a accredited veterinary laboratory in bacteriology and mycology is another important operation included in the group and alltogether we have a clear focus on Animal Health.<\/p>\n

Our investors section includes information regarding our market<\/a>, major shareholders<\/a>, corporate governance<\/a> and a financial calendar<\/a>. External analyzes of the company are conducted by Erik Penser Bank<\/a>, among others, and these are presented at Penser Access<\/a>.<\/p>\n

We look forward to you taking part of the information and hope to welcome you as a shareholder and to participate in an exciting development towards new, safe and effective vaccines within Animal Health.<\/p>\n\n

Events<\/h2>\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t
Date<\/th>Event<\/th>\n<\/tr>\n<\/thead>\n
September 10-13<\/td>BEVA Congress 2025<\/a>, Birmingham, UK<\/td>\n<\/tr>\n
October 2-4<\/td>Swedish Veterinary meeting 2025<\/a>, Uppsala<\/td>\n<\/tr>\n
October 16 - 17<\/td>HVFs h\u00f8stkurs<\/a>, Dilling, Norway<\/td>\n<\/tr>\n
October 23 - 24<\/td>Danish Veterinary Meeting 2025 <\/a>, K\u00f8benhavn<\/td>\n<\/tr>\n
November 20 - 21<\/td>London Vet Show 2025<\/a>, ExCeL London, UK<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n","protected":false},"excerpt":{"rendered":"

Intervacc develops veterinary vaccines based on fusions of recombinant proteins. Our first proprietary vaccine Strangvac\u00ae, a vaccine against the streptococcal infection strangles that affects horses, is now available in several important European markets. Strangvac\u00ae addresses a severe (fatal), common and highly contagious global disease. It is a vaccine with great coverage against all globally circulating […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":4,"comment_status":"closed","ping_status":"closed","template":"","meta":{"inline_featured_image":false},"_links":{"self":[{"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/pages\/789"}],"collection":[{"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/comments?post=789"}],"version-history":[{"count":16,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/pages\/789\/revisions"}],"predecessor-version":[{"id":691401,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/pages\/789\/revisions\/691401"}],"wp:attachment":[{"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/media?parent=789"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}